Mark T. Esser, PhD

Phylogenetic and alpha toxin variant analyses of Staphylococcus aureus strains isolated from patient
AstraZeneca

Disclosure: AstraZeneca (Employee, Shareholder)

Presentation(s):

• LB5 - PROVENT: Phase 3 Study of Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for Pre-exposure Prophylaxis of COVID-19 in Adults

  Thursday, September 30, 2021
  6:15 PM – 6:30 PM EDT